Patients suffering from advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations have emerged as groundbreaking treatment for with osimertinib, a potent EGFR TKI (TKI).The management of these patients is posed with a major challenge by the development of resistance to osimertinib.This article delves into the most common resistance mode to osimertinib and explores the fundamental mechanisms, diagnostic methods, treatment plans, and current research endeavors for overcoming this resistance.The most common resistance mechanism to osimertinib is characterized by the development of the T790M mutation in the EGFR catalytic domain, known…
